Cresset Asset Management’s C4 Therapeutics CCCC Stock Holding History

Cresset Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Hold	25,000	–	–	﹤0.01%	1651
2026 Q1	$65.8K	Hold	25,000	–	–	﹤0.01%	1568
2025 Q4	$47.8K	Hold	25,000	–	–	﹤0.01%	1615
2025 Q3	$55.5K	Hold	25,000	–	–	﹤0.01%	1526
2025 Q2	$35.8K	Sell	25,000 -978	-4%	-$1.42K	﹤0.01%	1396
2025 Q1	$41.6K	Buy	25,978 +978	+4%	+$2.92K	﹤0.01%	1664
2024 Q4	$90K	Hold	25,000	–	–	﹤0.01%	1633
2024 Q3	$143K	Hold	25,000	–	–	﹤0.01%	2009
2024 Q2	$116K	Buy	+25,000	New	+$149K	﹤0.01%	1940
2024 Q1	–	Sell	-25,000	Closed	-$141K	–	1917
2023 Q4	$141K	Hold	25,000	–	–	﹤0.01%	1731
2023 Q3	$46.5K	Buy	25,000 +5,000	+25%	+$15.3K	﹤0.01%	1751
2023 Q2	$55K	Buy	20,000 +8,719	+77%	+$28K	﹤0.01%	1842
2023 Q1	$35.4K	Sell	11,281 -34,600	-75%	-$204K	﹤0.01%	796
2022 Q4	$268K	Hold	45,881	–	–	﹤0.01%	563
2022 Q3	$402K	Sell	45,881 -5,536	-11%	-$57.5K	0.01%	574
2022 Q2	$387K	Buy	51,417 +6,036	+13%	+$53.1K	﹤0.01%	636
2022 Q1	$1.1M	Buy	45,381 +2,000	+5%	+$48.6K	0.01%	383
2021 Q4	$1.4M	Buy	+43,381	New	+$1.72M	0.01%	364

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cresset Asset Management's CCCC Position: Q2 2026 in Review

Cresset Asset Management held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 25,000 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #1651.

Cresset Asset Management first reported a position in CCCC in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.4M in Q4 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Cresset Asset Management held 25,000 shares of C4 Therapeutics worth $117K as of Q2 2026.
Cresset Asset Management left its C4 Therapeutics share count unchanged in Q2 2026.
C4 Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1651 holding.
Cresset Asset Management first reported a position in C4 Therapeutics in Q4 2021 and has held it in 18 quarters since.
Cresset Asset Management's C4 Therapeutics position peaked at $1.4M in Q4 2021.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.